Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 81

1.

A general framework for inhibitor resistance in protein kinases.

Balzano D, Santaguida S, Musacchio A, Villa F.

Chem Biol. 2011 Aug 26;18(8):966-75. doi: 10.1016/j.chembiol.2011.04.013. Erratum in: Chem Biol. 2011 Oct 28;18(10):1341.

PMID:
21867912
[PubMed - indexed for MEDLINE]
Free Article
2.

Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors.

Blencke S, Zech B, Engkvist O, Greff Z, Orfi L, Horváth Z, Kéri G, Ullrich A, Daub H.

Chem Biol. 2004 May;11(5):691-701.

PMID:
15157880
[PubMed - indexed for MEDLINE]
Free Article
3.

Irreversible protein kinase inhibitors.

Garuti L, Roberti M, Bottegoni G.

Curr Med Chem. 2011;18(20):2981-94. Review.

PMID:
21651479
[PubMed - indexed for MEDLINE]
4.

High affinity targets of protein kinase inhibitors have similar residues at the positions energetically important for binding.

Sheinerman FB, Giraud E, Laoui A.

J Mol Biol. 2005 Oct 7;352(5):1134-56.

PMID:
16139843
[PubMed - indexed for MEDLINE]
5.

Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling.

Gunby RH, Ahmed S, Sottocornola R, Gasser M, Redaelli S, Mologni L, Tartari CJ, Belloni V, Gambacorti-Passerini C, Scapozza L.

J Med Chem. 2006 Sep 21;49(19):5759-68.

PMID:
16970400
[PubMed - indexed for MEDLINE]
7.

Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket.

Gum RJ, McLaughlin MM, Kumar S, Wang Z, Bower MJ, Lee JC, Adams JL, Livi GP, Goldsmith EJ, Young PR.

J Biol Chem. 1998 Jun 19;273(25):15605-10.

PMID:
9624152
[PubMed - indexed for MEDLINE]
Free Article
9.

Structural basis for selective inhibition of Src family kinases by PP1.

Liu Y, Bishop A, Witucki L, Kraybill B, Shimizu E, Tsien J, Ubersax J, Blethrow J, Morgan DO, Shokat KM.

Chem Biol. 1999 Sep;6(9):671-8.

PMID:
10467133
[PubMed - indexed for MEDLINE]
Free Article
10.

Acquisition of inhibitor-sensitive protein kinases through protein design.

Bishop AC, Shokat KM.

Pharmacol Ther. 1999 May-Jun;82(2-3):337-46. Review.

PMID:
10454210
[PubMed - indexed for MEDLINE]
11.

Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors.

Zhu X, Kim JL, Newcomb JR, Rose PE, Stover DR, Toledo LM, Zhao H, Morgenstern KA.

Structure. 1999 Jun 15;7(6):651-61.

PMID:
10404594
[PubMed - indexed for MEDLINE]
12.

Chemoproteomic characterization of protein kinase inhibitors using immobilized ATP.

Duncan JS, Haystead TA, Litchfield DW.

Methods Mol Biol. 2012;795:119-34. doi: 10.1007/978-1-61779-337-0_8.

PMID:
21960219
[PubMed - indexed for MEDLINE]
13.

Chemical proteomic analysis reveals alternative modes of action for pyrido[2,3-d]pyrimidine kinase inhibitors.

Wissing J, Godl K, Brehmer D, Blencke S, Weber M, Habenberger P, Stein-Gerlach M, Missio A, Cotten M, Müller S, Daub H.

Mol Cell Proteomics. 2004 Dec;3(12):1181-93. Epub 2004 Oct 8.

PMID:
15475568
[PubMed - indexed for MEDLINE]
Free Article
14.

Molecular basis of drug resistance in aurora kinases.

Girdler F, Sessa F, Patercoli S, Villa F, Musacchio A, Taylor S.

Chem Biol. 2008 Jun;15(6):552-62. doi: 10.1016/j.chembiol.2008.04.013.

PMID:
18559266
[PubMed - indexed for MEDLINE]
Free Article
15.

ALK mutants in the kinase domain exhibit altered kinase activity and differential sensitivity to small molecule ALK inhibitors.

Lu L, Ghose AK, Quail MR, Albom MS, Durkin JT, Holskin BP, Angeles TS, Meyer SL, Ruggeri BA, Cheng M.

Biochemistry. 2009 Apr 28;48(16):3600-9. doi: 10.1021/bi8020923.

PMID:
19249873
[PubMed - indexed for MEDLINE]
16.

Structural biology contributions to tyrosine kinase drug discovery.

Cowan-Jacob SW, Möbitz H, Fabbro D.

Curr Opin Cell Biol. 2009 Apr;21(2):280-7. doi: 10.1016/j.ceb.2009.01.012. Epub 2009 Feb 7. Review.

PMID:
19208462
[PubMed - indexed for MEDLINE]
17.

Structural analysis of DFG-in and DFG-out dual Src-Abl inhibitors sharing a common vinyl purine template.

Zhou T, Commodore L, Huang WS, Wang Y, Sawyer TK, Shakespeare WC, Clackson T, Zhu X, Dalgarno DC.

Chem Biol Drug Des. 2010 Jan;75(1):18-28. doi: 10.1111/j.1747-0285.2009.00905.x. Epub 2009 Nov 5.

PMID:
19895503
[PubMed - indexed for MEDLINE]
18.

The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling.

Dar AC, Shokat KM.

Annu Rev Biochem. 2011;80:769-95. doi: 10.1146/annurev-biochem-090308-173656. Review.

PMID:
21548788
[PubMed - indexed for MEDLINE]
19.
20.

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.

Fabbro D, Ruetz S, Buchdunger E, Cowan-Jacob SW, Fendrich G, Liebetanz J, Mestan J, O'Reilly T, Traxler P, Chaudhuri B, Fretz H, Zimmermann J, Meyer T, Caravatti G, Furet P, Manley PW.

Pharmacol Ther. 2002 Feb-Mar;93(2-3):79-98. Review.

PMID:
12191602
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk